PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	**FOR FURTHER ACTION**	see Form PCT/ISA/220 as well as, where applicable, item 5 below.
019904003010		
International application No.	International filing date *(day/month/year)*	(Earliest) Priority Date *(day/month/year)*
PCT/US2005/000607	10/01/2005	09/01/2004
Applicant		
CORCEPT THERAPEUTICS, INC.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 7 sheets.

[X] It is also accompanied by a copy of each prior art document cited in this report.

1. **Basis of the report**
   a. With regard to the **language,** the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
      [ ] The international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).
   b. [ ] With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, see Box No. I.

2. [ ] **Certain claims were found unsearchable** (See Box II).

3. [ ] **Unity of invention is lacking** (see Box III).

4. With regard to the **title,**
   [X] the text is approved as submitted by the applicant.
   [ ] the text has been established by this Authority to read as follows:

5. With regard to the **abstract,**
   [ ] the text is approved as submitted by the applicant.
   [X] the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. With regard to the **drawings,**
   a. the figure of the **drawings** to be published with the abstract is Figure No. _____
      [ ] as suggested by the applicant.
      [ ] as selected by this Authority, because the applicant failed to suggest a figure.
      [ ] as selected by this Authority, because this figure better characterizes the invention.
   b. [ ] none of the figures is to be published with the abstract.

Box No. IV Text of the abstract (Continuation of item 5 of the first sheet)

The present invention provides a novel class of azadecalin compounds of formula (I) and methods of using the compounds as glucocorticoid receptor modulators.



(I).

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2005/000607

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D217/04 C07D405/06 C07D217/06 C07D217/08 C07D417/12
C07D413/14 C07D409/12 C07D409/14 C07D413/12 C07D513/06
C07D401/12 A61K31/4725 A61K31/472 A61P5/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, CHEM ABS Data, PAJ, WPI Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE CROSSFIRE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFT, FRANKFURT AM MAIN, DE; XP002327913 Database accession no. 101172-52-5 (BRN) abstract	1-3,5-7, 16,24
X	& YAKUGAKU ZASSHI, vol. 75, 1955, page 177, -----	1-3,5-7, 16,24
X	WO 94/10150 A (FOURNIER INDUSTRIE ET SANTE) 11 May 1994 (1994-05-11)	1-8,16, 17,24, 26,27
A	see formula III and preparation I and II for 3 specific compounds, 157048-15-2, 157048-16-3 and 157048-17-4 ----- -/--	1-33

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
24 May 2005	03/06/2005

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Scruton-Evans, I

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JP 04 368384 A (TORAY INDUSTRIES, INC, JAPAN) 21 December 1992 (1992-12-21) see compound 148254-51-7 (8a(iH)isoquinolinecarboxylic acid, 2,3,4,6,7,8-hexahydro-6-oxo-2-(2-propenyl) , ethyl ester	1-7,16, 24,26,27
X	JP 32 002220 B (TANABE DRUG MANUFG. CO) 11 April 1957 (1957-04-11) see 2nd and last compound in scheme, RN 101172-15-0 and 118899-01-7 (with R as Et)	1,5-7, 16,26
X	SCHULTZ, ARTHUR G. ET AL: "Heteroatom directed photoarylation. Synthetic potential of the heteroatom oxygen" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY , 100(7), 2150-62 CODEN: JACSAT; ISSN: 0002-7863, 1978, XP002327905 see compound 14, page 2151	1-7,16, 24,26,27
X	EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, vol. 2002, 2002, pages 1505-1508, XP002327906 see compound 8	1-7,17, 24,26,27
X	JOURNAL OF ORGANIC CHEMISTRY, vol. 64, no. 7, 1999, pages 2549-2554, XP002327907 see compounds (1) page 2549, 7,10,11,12 scheme 2, Table 1, compounds 13,7,14,15,21 and experimental, page 2553, 2nd compound and RN223788-80-5 and 223788-84-9	1-8,16, 17,24, 26,27
X	JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, no. 12, 1996, pages 2302-2312, XP002327908 see compound 5 (- and +) scheme 2, scheme 3, 7a 7b and RN 176797-08-3, 2(iH)isoquinolinecarboxylic acid,3,4,6,7,8,8a-hexahxdro-6-hydroxy-8ame thyl, ethylester cis	1-8,16, 17,24, 26,27
X	SCHULTZ, ARTHUR G. ET AL: "Studies directed at a synthesis of the morphine alkaloids. A photochemical approach" JOURNAL OF ORGANIC CHEMISTRY , 50(2), 217-31 CODEN: JOCEAH; ISSN: 0022-3263, 1985, XP002327909 see compound 7, scheme 1	1-7,17, 24,26,27

-/--

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	HSIN, LING-WEI ET AL: "Stereoselective synthesis of morphine fragments trans- and cis-octahydro-1H-benzo'4,5!furo'3,2-e!isoquinolines" TETRAHEDRON , 61(2), 513-520 CODEN: TETRAB; ISSN: 0040-4020, vol. 61, no. 2, 10 January 2005 (2005-01-10), pages 513-520, XP002327910 see compound 11	1,5-9, 11,16,24
P,X	ORGANIC LETTERS, vol. 6, no. 7, 3 February 2004 (2004-02-03), pages 1171-1173, XP002327911 see compounds 4,5,6,9a-j	1-7,17, 24,26,27
P,X	EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, vol. 2004, June 2004 (2004-06), pages 2701-2706, XP002327912 see compounds 2,7,10,11,4,5	1-8,16, 17,24, 26,27
X	JOURNAL OF SCIENTIFIC AND INDUSTRIAL RESEARCH, vol. 20b, 1961, pages 394-397, XP009047560 see compound VII, page 395	1-7,16, 24,26,27
X	PHARMACEUTICAL BULLETIN, vol. 4, 1956, pages 29-34, XP009047561 see compounds VII and X	1-5, 8-13,16, 24
P,X	ZEITSCHRIFT FÜR NATURFORSCHUNG B CHEMICAL SCIENCES, vol. 59, no. 4, 2004, pages 375-379, XP009047542 see compounds 6 and 7	1-8,24, 26,27
P,A	WO 2004/065351 A (NOVARTIS PHARMA GMBH) 5 August 2004 (2004-08-05) see formula Ih, page 20, example 46 and whole document	1-33
A	SPITZ I M ET AL: "MIFEPRISTONE (RU 486) - A MODULATOR OF PROGESTIN AND GLUCOCORTICOIDACTION" NEW ENGLAND JOURNAL OF MEDICINE, THE, MASSACHUSETTS MEDICAL SOCIETY, WALTHAM, MA, US, 1993, pages 404-412, XP000909997 ISSN: 0028-4793 the whole document	1-33

-/--

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ELMORE S W ET AL: "NONSTEROIDAL SELECTIVE GLUCOCORTICOID MODULATORS: THE EFFECT OF C-5 ALKYL SUBSTITUTION ON THE TRANSCRIPTIONAL ACTIVATION/REPRESSION PROFILE OF 2,5-DIHYDRO-10-METHOXY-2,2,4-TRIMETHYL-1H-Ä1ÜBENZOPYRANOÄ3 ,4-FÜQUINOLINES" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 44, no. 25, 2001, pages 4481-4491, XP001118988 ISSN: 0022-2623 the whole document -----	1-33

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US2005/000607

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9410150 A	11-05-1994	FR 2697252 A1	29-04-1994
		AT 148693 T	15-02-1997
		CA 2148002 A1	11-05-1994
		DE 69308029 D1	20-03-1997
		DE 69308029 T2	14-08-1997
		DK 666850 T3	28-07-1997
		EP 0666850 A1	16-08-1995
		ES 2098790 T3	01-05-1997
		WO 9410150 A1	11-05-1994
		GR 3023266 T3	30-07-1997
		JP 8504402 T	14-05-1996
		US 5580881 A	03-12-1996
JP 4368384 A	21-12-1992	JP 3160941 B2	25-04-2001
JP 32002220 B		NONE	
WO 2004065351 A	05-08-2004	WO 2004065351 A1	05-08-2004